This activity is supported by an educational grant from Lilly.
Anna D. Burke, MD
Karsten Solheim Chair for Dementia
Director of Alzheimer’s and Memory Disorders Division
Karsten Solheim Chair for Dementia
Director of Alzheimer’s and Memory Disorders Division
Director of Neuropsychiatry
Department of Neurology
Barrow Neurological Institute
Phoenix, AZ
The Effects of Race and Gender on Amyloid Positivity, Chair: Suzanne Schindler, Washington University St. Louis, St. Louis, MO (United States)
1. Amyloid PET results from the GAP Bio-Hermes study: initial findings on differences between racial and ethnic groups, Robin Wolz, IXICO, London (United Kingdom)
2. Race and Sex Effects on Rates of Amyloid Positivity in Real-World Memory Care: Insights from IDEAS and New IDEAS, Charles Windon, Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco – San Francisco (United States)
Earn credit by taking a few minutes to participate in CME Outfitters Reinforcing Reflections, a text-based reflection of how a topic or concept connects to your clinical practice & professional life.
Donanemab in Early Symptomatic Alzheimer’s Disease: Additional Insights from TRAILBLAZER-ALZ 2, Chair: Takeshi Iwatsubo, The University of Tokyo, Tokyo (Japan)
1. Safety Insights from the Donanemab Trials, Steve Greenberg, Harvard Medical School and Massachusetts General Hospital, Boston, MA (United States)
2. Predicting Efficacy in Donanemab-Treated Participants, Mark Mintun, Eli Lilly and Company, Indianapolis, IN and Avid Radiopharmaceuticals, Inc. Philadelphia, PA (United States)
Lecanemab for Early Alzheimer’s Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration, Chair: Christopher van Dyck, Yale Alzheimer’s Disease Research Center – New Haven (United States)
1. Clarity AD: Review of the Mechanism-Based Rationale and Results of the Lecanemab Phase 3 Trial, Christopher van Dyck, Yale Alzheimer’s Disease Research Center – New Haven (United States)
2. Biomarker Assessments from Clarity AD: Downstream Implications of Targeting Protofibrils and Tau as a Predictive Biomarker, Keith Johnson, Harvard Medical School – Boston (United States)
3. Lecanemab for the Treatment of Early Alzheimer’s Disease: The Extension of Efficacy Results from Clarity AD, Reisa Sperling, Brigham and Women’s Hospital Harvard Medical School – Boston (United States)
4. Preliminary Update on Lecanemab Safety in Clarity AD Open-Label Extension, Including Subcutaneous Formulation, Michael Irizarry, Eisai Inc. – Nutley (United States)
Earn credit by taking a few minutes to participate in CME Outfitters Reinforcing Reflections, a text-based reflection of how a topic or concept connects to your clinical practice & professional life.
3. Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s Disease, Robert Rissman, Alzheimer, University California San Diego – San Diego (United States)
Earn credit by taking a few minutes to participate in CME Outfitters Reinforcing Reflections, a text-based reflection of how a topic or concept connects to your clinical practice & professional life.
1. Quantitative Amyloid-PET in Real-World Practice: Lessons from the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study, Renaud La Joie, University of California, San Francisco – San Francisco, CA (United States)
2. Establishing the validity of a novel electronic Clinical Dementia Rating (eCDR), Rachel Nosheny, UCSF – San Francisco (United States)
Earn credit by taking a few minutes to participate in CME Outfitters Reinforcing Reflections, a text-based reflection of how a topic or concept connects to your clinical practice & professional life.